Andreas Gal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andreas Gal has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
Michael Beck
5 shared publicationsCordula Steglich
Institut für Humangenetik, Universitäts‐Krankenhaus Eppendorf, Hamburg, Germany
2 shared publications- Debra A. Thompson
Department of Ophthalmology, University of Michigan, Ann Arbor, MI 48105, USA
2 shared publications Eberhart Zrenner
Centre for Ophthalmology, Institute for Ophthalmic Research, University of Tübingen, D-72076 Tübingen, Germany
2 shared publications- Hanno Joern Bolz
Institute of Human Genetics, Faculty of Medicine, University Hospital of Cologne, University of Cologne, Cologne, Germany
2 shared publications Isabella Rau
Institut für Humangenetik, Universitätsklinikum Hamburg-Eppendorf, D-20246 Hamburg, Germany
2 shared publications
Latest Publications
- Open Access
- 10 February 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-10
OSBPL2 encodes a protein of inner and outer hair cell stereocilia and is mutated in autosomal dominant hearing loss (DFNA67)
Early-onset hearing loss is mostly of genetic origin. The complexity of the hearing process is reflected by its extensive genetic heterogeneity, with probably many causative genes remaining to be identified. Here, we aimed at identifying the genetic basis for autosomal dominant non-syndromic hearing loss (ADNSHL) in a large German family. A panel of 66 known deafness genes was analyzed for mutations by next-generation sequencing (NGS) in the index patient. We then conducted genome-wide linkage analysis, and whole-exome sequencing was carried out with samples of two patients. Expression of Osbpl2 in the mouse cochlea was determined by immunohistochemistry. Because Osbpl2 has been proposed as a target of miR-96, we investigated homozygous Mir96 mutant mice for its upregulation. Onset of hearing loss in the investigated ADNSHL family is in childhood, initially affecting the high frequencies and progressing to profound deafness in adulthood. However, there is considerable intrafamilial variability. We mapped a novel ADNSHL locus, DFNA67, to chromosome 20q13.2-q13.33, and subsequently identified a co-segregating heterozygous frameshift mutation, c.141_142delTG (p.Arg50Alafs*103), in OSBPL2, encoding a protein known to interact with the DFNA1 protein, DIAPH1. In mice, Osbpl2 was prominently expressed in stereocilia of cochlear outer and inner hair cells. We found no significant Osbpl2 upregulation at the mRNA level in homozygous Mir96 mutant mice. The function of OSBPL2 in the hearing process remains to be determined. Our study and the recent description of another frameshift mutation in a Chinese ADNSHL family identify OSBPL2 as a novel gene for progressive deafness.
- 10 February 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-10
Open AccessOSBPL2 encodes a protein of inner and outer hair cell stereocilia and is mutated in autosomal dominant hearing loss (DFNA67)
Early-onset hearing loss is mostly of genetic origin. The complexity of the hearing process is reflected by its extensive genetic heterogeneity, with probably many causative genes remaining to be identified. Here, we aimed at identifying the genetic basis for autosomal dominant non-syndromic hearing loss (ADNSHL) in a large German family. A panel of 66 known deafness genes was analyzed for mutations by next-generation sequencing (NGS) in the index patient. We then conducted genome-wide linkage analysis, and whole-exome sequencing was carried out with samples of two patients. Expression of Osbpl2 in the mouse cochlea was determined by immunohistochemistry. Because Osbpl2 has been proposed as a target of miR-96, we investigated homozygous Mir96 mutant mice for its upregulation. Onset of hearing loss in the investigated ADNSHL family is in childhood, initially affecting the high frequencies and progressing to profound deafness in adulthood. However, there is considerable intrafamilial variability. We mapped a novel ADNSHL locus, DFNA67, to chromosome 20q13.2-q13.33, and subsequently identified a co-segregating heterozygous frameshift mutation, c.141_142delTG (p.Arg50Alafs*103), in OSBPL2, encoding a protein known to interact with the DFNA1 protein, DIAPH1. In mice, Osbpl2 was prominently expressed in stereocilia of cochlear outer and inner hair cells. We found no significant Osbpl2 upregulation at the mRNA level in homozygous Mir96 mutant mice. The function of OSBPL2 in the hearing process remains to be determined. Our study and the recent description of another frameshift mutation in a Chinese ADNSHL family identify OSBPL2 as a novel gene for progressive deafness.
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S78
Increase in left ventricular mass index and acroparesthesia incidence in children with Fabry disease correlates with their GLA mutation
- 1 February 2013
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 108 (2) , S78
Increase in left ventricular mass index and acroparesthesia incidence in children with Fabry disease correlates with their GLA mutation
- 9 November 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (3) , 1-3
Clinical utility gene card for: Adrenoleukodystrophy
- 9 November 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (3) , 1-3
Clinical utility gene card for: Adrenoleukodystrophy
- 21 September 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (2) , 3
Clinical utility gene card for: Fabry disease
- 21 September 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (2) , 3
Clinical utility gene card for: Fabry disease
- Open Access
- 24 August 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (1) , 2
Clinical utility gene card for: Mucopolysaccharidosis type II
- 24 August 2011
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 20 (1) , 2
Open AccessClinical utility gene card for: Mucopolysaccharidosis type II
- 1 March 2011
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 88 (3) , 382-390
Autosomal-Recessive Posterior Microphthalmos Is Caused by Mutations in PRSS56, a Gene Encoding a Trypsin-Like Serine Protease
- 1 March 2011
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 88 (3) , 382-390
Autosomal-Recessive Posterior Microphthalmos Is Caused by Mutations in PRSS56, a Gene Encoding a Trypsin-Like Serine Protease
- Open Access
- 13 January 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 509-514
Toward a consensus in the laboratory diagnostics of Fabry disease ‐ recommendations of a European expert group
- 13 January 2011
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 34 (2) , 509-514
Open AccessToward a consensus in the laboratory diagnostics of Fabry disease ‐ recommendations of a European expert group
- 1 September 2010
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 87 (3) , 376-381
Nonsense Mutations in FAM161A Cause RP28-Associated Recessive Retinitis Pigmentosa
- 1 September 2010
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 87 (3) , 376-381
Nonsense Mutations in FAM161A Cause RP28-Associated Recessive Retinitis Pigmentosa
- 10 July 2010
- Published by Springer Nature
- p. 3-19
Molecular Genetics of Fabry Disease and Genotype–Phenotype Correlation
- 10 July 2010
- Published by Springer Nature
- p. 3-19
Molecular Genetics of Fabry Disease and Genotype–Phenotype Correlation
- 22 October 2008
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 31 (S2) , 349-356
Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease
Fabry disease is an X-chromosomal storage disorder due to loss-of-function mutations of the GLA gene encoding the lysosomal enzyme α-galactosidase A. Accumulating glycosphingolipid deposits disturb the function of various cells, in particular that of myocytes, arterial smooth-muscle cells, and vascular endothelium. Hypertrophic cardiomyopathy, for example measured by left posterior wall thickness (LPWT) of the heart, represents a major component of Fabry disease morbidity in adult patients. Endothelium-derived nitric oxide (eNO), produced by eNO synthase (eNOS), is a key regulator of vessel wall function and cardiovascular homeostasis. We analysed the effect of the polymorphisms c.894G > T (p.Glu298Asp) in exon 7 and the 27 bp tandem repeat (VNTR; allele a: 4 and allele b: 5 repeats) in intron 4 of the NOS3 gene, encoding eNOS, on LPWT of 102 patients with Fabry disease. For the association analysis, the distance of each patient’s LPWT value from the cohort-specific, age-dependent regression line point (expected values) was used. In the cohort of 46 male patients, LPWT mean value of the group with GG genotype at position c.894 was smaller by 1 mm than that of (GT + TT) (p = 0.058). LPWT of patients with bb was thicker by 1.4 mm than that of (ab + aa) (p = 0.022). In patients with haplotype Ga, a thinner LPWT was seen than in those with Tb (p = 0.006). While no correlation was found between the GLA genotype and LPWT, the difference of 2.44 mm between the relative LPWT mean values of the two extreme NOS3 groups corresponds to the absolute LPWT increase that an average male patient with Fabry disease experiences during about 12 years. These are the first data showing a significant association of non-GLA-derived sequence variants with the cardiac phenotype in Fabry disease that may in part explain the great phenotypic variability of the disease.
- 22 October 2008
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 31 (S2) , 349-356
Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease
Fabry disease is an X-chromosomal storage disorder due to loss-of-function mutations of the GLA gene encoding the lysosomal enzyme α-galactosidase A. Accumulating glycosphingolipid deposits disturb the function of various cells, in particular that of myocytes, arterial smooth-muscle cells, and vascular endothelium. Hypertrophic cardiomyopathy, for example measured by left posterior wall thickness (LPWT) of the heart, represents a major component of Fabry disease morbidity in adult patients. Endothelium-derived nitric oxide (eNO), produced by eNO synthase (eNOS), is a key regulator of vessel wall function and cardiovascular homeostasis. We analysed the effect of the polymorphisms c.894G > T (p.Glu298Asp) in exon 7 and the 27 bp tandem repeat (VNTR; allele a: 4 and allele b: 5 repeats) in intron 4 of the NOS3 gene, encoding eNOS, on LPWT of 102 patients with Fabry disease. For the association analysis, the distance of each patient’s LPWT value from the cohort-specific, age-dependent regression line point (expected values) was used. In the cohort of 46 male patients, LPWT mean value of the group with GG genotype at position c.894 was smaller by 1 mm than that of (GT + TT) (p = 0.058). LPWT of patients with bb was thicker by 1.4 mm than that of (ab + aa) (p = 0.022). In patients with haplotype Ga, a thinner LPWT was seen than in those with Tb (p = 0.006). While no correlation was found between the GLA genotype and LPWT, the difference of 2.44 mm between the relative LPWT mean values of the two extreme NOS3 groups corresponds to the absolute LPWT increase that an average male patient with Fabry disease experiences during about 12 years. These are the first data showing a significant association of non-GLA-derived sequence variants with the cardiac phenotype in Fabry disease that may in part explain the great phenotypic variability of the disease.